Letter to the Editor
Copyright ©The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Cardiol. Sep 26, 2024; 16(9): 546-549
Published online Sep 26, 2024. doi: 10.4330/wjc.v16.i9.546
Medical dilemma: Programmed death 1 blockade (sintilimab) therapy in patients suffering from tumours combined with psoriasis
Di Jin, Yu-Wei Wang, Zhi-Min Lin, Chen Li, Ming Li
Di Jin, Ming Li, Department of Rheumatology, Weifang People’s Hospital, Weifang 261000, Shandong Province, China
Yu-Wei Wang, Department of Cardiology, Yidu Central Hospital of Weifang, Weifang 261000, Shandong Province, China
Zhi-Min Lin, Third Affiliated Hospital, Beijing University of Chinese Medicine, Beijing 100020, China
Chen Li, Department of Rheumatology, Fangshan Hospital, Beijing University of Chinese Medicine, Beijing 102400, China
Co-first authors: Di Jin and Yu-Wei Wang.
Co-corresponding authors: Ming Li and Chen Li.
Author contributions: Jin D and Wang YW prepared the manuscript and contributed equally to this article, ensuring a cohesive presentation of the research findings; Jin D and Lin ZM were responsible for the meticulous analysis and interpretation of the case, providing essential insights that underpinned the study's conclusions; Li C and Li M were at the helm of conceptualizing and designing the research ideas, setting the stage for the study with their innovative and well-defined framework; All authors have read and approved the final manuscript, with Jin D and Wang YW recognized as co-first authors for their significant contributions to the manuscript preparation, and the collaborative efforts of the team were instrumental in bringing the research to fruition.
Supported by Weifang Health Commission's Scientific Research Program, No. WFWSJK-2023-222 and No. WFWSJK-2023-240; and the Weifang Young Medical Talent Support Project.
Conflict-of-interest statement: All the authors declare that they have no conflict of interest.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Ming Li, MD, Chief Doctor, Staff Physician, Department of Rheumatology, Weifang People’s Hospital, No. 151 Guangwen Street, Kuiwen District, Weifang 261000, Shandong Province, China. lalwlm@aliyun.com
Received: June 15, 2024
Revised: August 16, 2024
Accepted: September 10, 2024
Published online: September 26, 2024
Processing time: 96 Days and 8.1 Hours
Core Tip

Core Tip: The major strategies for dealing with immune-related adverse events should include scientific awareness, early diagnosis and graded management. The important direction of tumour immunotherapy research is how to reduce the adverse effects of immunotherapy and can improve the quality of patient survival. The correlation between programmed cell death protein-1 inhibitors and chronic psoriasis is gradually receiving more and more attention, and how to screen high-risk populations in the future, as well as to give the necessary and effective preventive therapeutic measures still need to be further explored.